Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Ultragenyx Pharma (RARE) Announces Proposed $300M Share Offering
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
-
Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
-
Ultragenyx Pharma (RARE) Sells Portion of Future North American Royalties on Crysvita for $500M to OMERS
-
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
-
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
-
Ultragenyx to Participate in the Cowen Health Care Conference
-
Ultragenyx to Participate in the Cowen Health Care Conference
-
Ultragenyx Pharma (RARE) PT Lowered to $124 at Cowen, Following Earnings
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Ultragenyx Pharma (RARE) Prices 4.44M Share Common Offering at $90/Sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Pharma (RARE) Announces Proposed $400M Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen
-
Ultragenyx Pharma (RARE) PT Raised to $75 at Cowen
-
Ultragenyx Pharma (RARE) PT Raised to $79 at Cowen on Strong Crysvita Sales
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Pharma (RARE) Prices 5.07M Share Common Offering at $60/Sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Cowen Starts Ultragenyx Pharma (RARE) at Outperform
-
Ultragenyx Pharma (RARE) to Offer Up to $250M in CommonStock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Pharma (RARE) Prices 4.386M Share Common Offering at $57/Sh
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Announces Pricing of Public Offering of Common Stock
-
Ultragenyx Pharma (RARE) Plans $175M Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Announces Proposed Public Offering of Common Stock
-
Ultragenyx Pharma (RARE): NDR Focuses On Burosumab, Reit Outperform - Cowen
-
Cowen Reiterates Outperform Rating on Ultragenyx Pharma (RARE); 'Phase III Burosumab Data Supportive Of A Broad XLH Label'
-
Ultragenyx to Present at Upcoming Investor Conferences
-
Ultragenyx Pharma (RARE) Discloses $150M At-The-Market Offering Through Cowen
-
Pre-Open Stock Movers 06/17: (RDEN) (PRTK) (FNSR) (SHWC) (LL) Higher; (GLYC) (CMTL) Lower (more...)
-
Ultragenyx to Present at the Cowen and Company 36th Annual Health Care Conference
-
Pre-Open Stock Movers 07/27: (MAG) (TEVA) (AGN) Higher; (BLPH) (MYL) (GRUB) Lower (more...)
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
-
Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
-
Ultragenyx Pharma (RARE) Prics 2.2M Common Stock Offering at $120/Share